| Literature DB >> 15298072 |
Abstract
GW Pharmaceuticals is developing GW-1000 (Sativex), a narrow ratio delta9-tetrahydrocannabinol:cannabidiol product for the potential treatment of multiple sclerosis, spinal cord injury, neurogenic pain and peripheral neuropathy. In March 2003, the company filed for approval for the treatment of MS with the UK Medicines Control Agency, and in May 2004, filed for new drug submission with Health Canada.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15298072
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472